Compumedics Limited · ASX:CMP
Compumedics — Investor Presentation (October 2021)
24 slides from Compumedics's investor presentation, October 2021
Slide 1: Corporate Presentation October 2021
Corporate presentation September 2016 Cover sheet to be added – Simone Corporate Presentation October 2021 David Burton – Chairman, CEO dburton@compumedics.com.au David Lawson – Director, CFO dlawson@compumedics.com.au Sleep Diagnostics & Treatment - Neuro Diagnostics - Brain Research - Ultrasonic B
Slide 2: Who is Compumedics?
Who is Compumedics? A leading global, innovative developer and manufacturer of medical devices for: Monitoring neurological Ultrasonic monitoring of Diagnosing disorders including long- Highly sophisticated blood flow through the sleep disorders term epilepsy monitoring brain research brain (Transcr
Slide 3: FY2021 – Performance Review
FY2021 – Performance Review ▪ Revenue $35.7m, EBITDA $2.6m, NPAT $1.0m FY21 FY20 Variance Comment Revenues stabilised and resumed growth as Revenue $35.7m $35.1m 2% COVID-19 impacts lessened as FY21 progressed. Underlying profitability improved as sales EBITDA – increased and tight cost control rema
Slide 4: FY2021 – Performance Review
FY2021 – Performance Review ▪ Core: Europe rebounded well in FY21 with revenues increasing 49% over the prior period, this was driven by revenue increases in France, Germany and the DWL business. ▪ Core: Increases in Europe were off-set by declines in the USA based business, down 17% and Asia (inclu
Slide 5: Revenue Composition at $35.7m
Revenue Composition at $35.7m 30 June 2021 By geographic region By product/market Customer Consumables Care 9% 10% Europe, USA, 29% 31% Brain - Sleep - Blood Flow Clinical Monitoring Diagnostics 21% 28% Sleep - Aust, 13% Brain - Nexus360 Research Asia, 27% 15% Brain - Clinical2% Monitoring 15% Softw
Slide 6: Revenue Bridge Chart – FY20 to FY21
Revenue Bridge Chart – FY20 to FY21 6
Slide 7: EBITDA Bridge Chart – FY20 to FY21
EBITDA Bridge Chart – FY20 to FY21 7
Slide 8: Core Business – COVID-19 impacts absorbed, profits continue
Core Business – COVID-19 impacts absorbed, profits continue 8
Slide 9: Core Business – Consistent Net Cash Position
Core Business – Consistent Net Cash Position $m FY16 FY17 FY18 FY19 FY20 FY21 Cash 3.1 4.1 3.9 4.6 6.4 6.8 Trade receivables 11.9 13.1 18.3 16.0 12.6 13.0 Inventories 6.5 7.4 7.6 7.8 8.8 9.7 Capitalised R&D 2.4 2.4 4.0 6.8 2.8 4.1 Tax asset 0.5 0.8 0.1 0.0 0.8 0.8 PP&E 0.8 0.7 0.7 1.7 1.5 1.0 Other
Slide 10: China - We are the number 1 Premier Supplier
China - We are the number 1 Premier Supplier Compumedics Clients in China Sleep Neuroscience Neuroscan 28 2 Xin Jiang 5 Helongjiang Inner Mongolia 2 Jilin China Sales (invoiced) – USD’s Beijing 88 23 2 Liaoning Ningxia Qinhuangdao QingHai 3 HeBei 10 3 Tianjin Dalian 2 3 16 9.6 Gansu 14 HeNan 12 Welf
Slide 11: Growth Platform – Core and Step-Out
Growth Platform – Core and Step-Out Sales – schematic only FY19A FY20A FY21A FY22F FY23F FY24F Core - Base Core - Sleep/Neuro (Mid Market) Neuro - MEG Sleep - eHealth (Nexus360 & Somfit) • Step-out - NEURO – BRAIN IMAGING – First phase installation at Barrow Neurological Institute in Phoenix, AZ, US
Slide 12: Core Business – Premium Focus
Core Business – Premium Focus Neuro Neuro Sleep Brain Blood Diagnostics – Diagnostics - Diagnostics Flow Diagnostics Clinic Research Global market – 250m 1,300m 20m 15m USD pa Compumedics market share 6% <1% 30% 35% (approximate) Aust – 1 Aust – 1 Aust – 1 Aust – 1 Compumedics USA – 2 USA – 3 USA –
Slide 13: Core Business - Growth Drivers
Core Business - Growth Drivers Compumedics/Neuroscan innovative brain analysis software and high-performance amplifiers are unrivalled world class technology. We have about 23,000 systems installed worldwide. Strong reputation and brand name. Customers like buying from Compumedics. Earnings initiati
Slide 14: Core Business: New products > New markets (Falcon HST)
Core Business: New products > New markets Falcon HST ➢ A new generation of home or professional user experience for the home sleep testing market. Compumedics regulatory phases have now advanced to enable market release activities for this new device ➢ Will fully integrate with Compumedics existing
Slide 15: Falcon HST – market drivers
Core Business: New products > New markets Falcon HST – market drivers ➢ The market opportunity (estimates to assist OSA sufferers) – USA 54m people, USD2.7b pa, Europe 66m people, USD 2.6b pa, Asia 77m, USD1.9b pa ➢ 26%1 of adults worldwide, including 54M in the US alone, suffer from sleep apnea. Ab
Slide 16: Core Business: New products > New markets (Okti)
Core Business: New products > New markets Okti ➢ Best in class ambulatory, home or clinical EEG monitoring device, scalable from 32 channels up to 256 channels for routine EEG monitoring through to long-term epilepsy monitoring, including high density EEG capabilities ➢ Can be combined with Compumed
Slide 17: Core Business: New Products > New Markets (CURRY)
Core Business: New Products > New Markets CURRY 9 ➢ Compumedics class leading brain analysis software includes spike/seizure detection routines for the first time, incorporating artificial intelligence machine learning algorithms, enabling clinicians to quickly isolate epileptogenic activity ➢ No ot
Slide 18: Next Generation Growth – Core and Step-out
Next Generation Growth – Core and Step-out Neuro Sleep Neuro Brain Blood Diagnostics – Diagnostics Diagnostics - Imaging Flow Diagnostics Clinic Cloud based sleep Long term epilepsy Leverage existing TCD Leverage CURRY Next generation diagnostic platforms for market penetration into technology and p
Slide 19: Step out - Brain Imaging
Step out 1 - Brain Imaging: Opportunity Market & Competition Plan Outcome CMP’s CURRY brain analysis The MEG market is currently estimated FY22 – second and final FY19/FY20 CMP software is already the gold at about 20 systems a year at an phase of MEG has sold and standard for the MEG* market averag
Slide 20: Step out - eHealth – Cloud Sleep Diagnostics
Step out 2 - eHealth – Cloud Sleep Diagnostics Nexus 360 Operational systems have been Compumedics is Key partners (professional developed for the cloud-based continuing to seek being pursued cloud sleep capture, transfer and translation of appropriate third include web, diagnostics) sold medical gr
Slide 21: Directors & Executive Team Key Management
Directors & Executive Team Key Management David Burton, Ph.D. Executive Chairman, CEO Founder, Tenure 32 yrs Mr Tucson Dunn Mr. David Lawson Non Executive Director Chief Financial Officer CMP Tenure 12 months & Company Secretary CMP Tenure 20 yrs Mr. Warwick Freeman Kerry Hubick, Ph.D. Mr. Christoph
Slide 22: Investor Summary
Investor Summary Core business profitable with on-going growth opportunities in key global markets International sales force Compumedics remains expansion, neurology and sleep committed to continuing to market opportunity and earnings deliver superior returns to improvement initiatives to continue s
Slide 23: Disclaimer
Disclaimer This presentation has been prepared by Compumedics Ltd (CMP). While the information in this presentation has been prepared in good faith and with reasonable care, no representation or warranty, express or implied, is made as to the accuracy, adequacy or reliability of any statement, estim
Slide 24: compumedics.com.au 24
© COMPUMEDICS OVER 3 YEARS INOIMGNOSTICS www.compumedics.com